Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Free Cash Flow (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Free Cash Flow for 4 consecutive years, with -$2.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 44.11% to -$2.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$8.5 million, a 17.02% decrease, with the full-year FY2024 number at -$7.3 million, down 21.17% from a year prior.
  • Free Cash Flow was -$2.5 million for Q3 2025 at bioAffinity Technologies, up from -$2.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$376141.0 in Q2 2022 to a low of -$2.7 million in Q2 2025.
  • A 4-year average of -$1.6 million and a median of -$1.6 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 262.58% in 2023, then rose 29.1% in 2025.
  • bioAffinity Technologies' Free Cash Flow stood at -$1.3 million in 2022, then fell by 23.24% to -$1.6 million in 2023, then fell by 4.64% to -$1.7 million in 2024, then plummeted by 47.67% to -$2.5 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Free Cash Flow are -$2.5 million (Q3 2025), -$2.7 million (Q2 2025), and -$1.7 million (Q1 2025).